Oncimmune Hldngs PLC - Exercise of Options
Exercise of Options
Application has been made to the
The Company advises that, following Admission, the Company's issued share capital will be 63,510,047 Ordinary Shares all with voting rights. The above figure of 63,510,047 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the
For further information:
+44 (0)20 3829 5000
finnCap (Joint Broker)
+44 (0)20 7220 0500
+44 (0)20 3727 1000
Our intimate understanding of the human immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies.
The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and give people extra time.
The unique combination of our core technology and understanding of the immune system, powers our ImmunoINSIGHTS service; a proprietary platform that enables life science organisations to optimise drug development and delivery, leading to more effective, targeted as well as safer treatments for patients.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
Quick facts: Oncimmune
Market Cap: £88.6 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE